Astellas’ Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for $609 Million

Tokyo - June 30, 2011 - Astellas Pharma Inc. announced today that Prosidion’s patent estate and associated royalty stream relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes has been sold to Royalty Pharma for a total cash payment of $609 million. The transaction is expected to close in July 2011.


© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.